WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130421
CAS#: N/A
Description: CG13250 is a BET bromodomain inhibitor that is orally bioavailable. CG13250 has been shown to be efficacious is a xenograft mouse model of leukemia.
Hodoodo Cat#: H130421
Name: CG13250
CAS#: N/A
Chemical Formula: C21H19N3O2
Exact Mass: 345.15
Molecular Weight: 345.400
Elemental Analysis: C, 73.03; H, 5.54; N, 12.17; O, 9.26
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CG13250; CG 13250; CG-13250
IUPAC/Chemical Name: 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one
InChi Key: ZZEQMSXTKAJTLH-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H19N3O2/c1-13-21(14(2)26-24-13)16-8-9-18-17(10-16)19(11-20(25)23-18)22-12-15-6-4-3-5-7-15/h3-11H,12H2,1-2H3,(H2,22,23,25)
SMILES Code: O=C1NC2=C(C=C(C3=C(C)ON=C3C)C=C2)C(NCC4=CC=CC=C4)=C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 345.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Imayoshi N, Yoshioka M, Chauhan J, Nakata S, Toda Y, Fletcher S, Strovel JW, Takata K, Ashihara E. CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model. Biochem Biophys Res Commun. 2017 Mar 4;484(2):262-268. doi: 10.1016/j.bbrc.2017.01.088. Epub 2017 Jan 20. PMID: 28115161.
2. Chauhan J, Yoshioka M, Pogash S, Strovel JW, Fletcher S. Discovery and anti-tumor activity of 4-(benzylamino)-6-(3,5-dimethylisoxazol-4-yl)quinolin-2(1H)-one (CG13250), a potent, selective and orally bioavailable BET bromodomain inhibitor. Bioorg Med Chem Lett. 2023 Apr 15;86:129220. doi: 10.1016/j.bmcl.2023.129220. Epub 2023 Mar 9. PMID: 36905966.